share_log

奥泰生物(688606.SH)：上半年净利润1.2亿元 同比增长74.03%

Aotecar Biology (688606.SH): The net income in the first half of the year was 0.12 billion yuan, a year-on-year increase of 74.03%.

Gelonghui Finance ·  Aug 30 03:49

On August 30th, Glory Meditech Co., Ltd. (688606.SH) released its semi-annual report. The company's revenue in the first half of the year was 396.5034 million yuan, an increase of 2.23% compared to the same period last year. Among them, the revenue of the company's infectious disease testing products was 166.2669 million yuan, an increase of 31.10% compared to the same period last year. The revenue of drug and substance abuse testing products was 102.3142 million yuan, an increase of 9.25% compared to the same period last year. The revenue of tumor marker testing products and myocardial marker testing products was 20.264 million yuan, an increase of 26.55% compared to the same period last year. The revenue of women's health testing products, COVID-19 individual testing products, and other category testing products were 35.9777 million yuan, 25.8002 million yuan, and 4,447.01 million yuan, respectively. The company achieved a net income of 123.8794 million yuan attributable to shareholders of the listed company, an increase of 74.03% compared to the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment